back spasms

PhIII failure triggers layoffs, spending cuts and warning of 'dissolution' for single-minded biotech
Endpoints
Wed, 03/23/22 - 10:34 am
Neurana Pharmaceuticals
clinical trials
tolperisone
back spasms
layoffs